Acute Lymphoblastic Leukemia Clinical Trial
Official title:
Aerobic and Strengthening Exercise for Acute Leukemia
Survivors of childhood leukemia have muscle weakness and impaired mobility (physical performance), a higher than expected frequency of obesity, and early mortality from cardiovascular disease. Treatment related neuropathy, cardiotoxicity and general cachexia may complicate physical performance and establish a pattern of sedentary behavior that may lead to a lifetime of inactivity. There is limited evidence that children being treated for leukemia benefit from home exercise programs during the maintenance phase of therapy, particularly in terms of muscle strength and range of motion. However, there are no established guidelines regarding the prescription of exercise for children diagnosed with leukemia. We propose to test the feasibility of an exercise intervention among children being treated for acute lymphoblastic leukemia (ALL) and hypothesize that children who participate in the exercise intervention will demonstrate improvements in gross motor function, strength, flexibility, and cardio respiratory fitness, and that they will have more favorable body composition when compared to the children who are assigned to the usual activity group.
The purpose of this trial is to determine the feasibility of an aerobic and strengthening
exercise intervention trial among children during maintenance therapy for childhood ALL by
evaluating participant accrual, participant compliance, and burden to the institutional
staff.
We anticipate that key barriers exist which threaten the successful completion of an
interventional trial of exercise within the ALL patient population. Approximately 2,500 to
3,500 children are diagnosed each year with ALL and similar numbers will enter the
maintenance phase of therapy during a given year. About 22% of those diagnosed are between 5
and 8 years old. Thus accrual is limited by the small patient population but fortunately
most patients with ALL receive their care at dedicated pediatric oncology institutions. Lack
of interest or lack of understanding of the underlying problem of obesity and weakness among
survivors in the ALL population may be additional barriers to accrual. In addition, families
may be overwhelmed by the primary diagnosis of leukemia and feel that they are unable to
take on additional challenges.
Compliance to a rigorous exercise regimen must be ascertained if demonstrable improvement in
motor performance, body composition and cardiovascular disease risk profile are to occur.
Key to this study is not only short-term compliance but designing an intervention that will
promote and improve long-term rates of exercise. Barriers to compliance include length of
time to complete the intervention, number of days the intervention must be administered,
perceived benefit by the participant, difficulty of the intervention, inadequate
demonstration of the intervention, poor understanding by the participant/parent of the
importance of obesity and weakness among survivors of childhood ALL, and health issues in
regard to the primary diagnosis of ALL.
We will open a feasibility study at 3 institutions dedicated to treatment of childhood
cancer: St. Jude Children's Research Hospital, Oregon Health & Science University and
Vanderbilt Ingram Cancer Center .The accrual goal of this study will be a total of 20
patients. The hypothesized outcome for this aim of the feasibility study will be an accrual
rate of 50% of eligible patients at a given institution.
Motor Function The Bruinicks-Osteretsky Test of Motor Proficiency Version 2 (BOT-2) will be
used to measure participants' motor function. Maximum isometric knee extension strength will
be measured with a hand held myometer and hand grip strength will be measured with a hand
held dynamometer. Additionally, flexibility will be measured with the sit and reach test.
Ankle dorsiflexion active and passive range of motion will be measures with a goniometer.
Aerobic capacity will be measured with the modified Cooper 6 minute walk test. Body
composition and vital signs will also be collected.
Intervention Participants will receive counseling and written material regarding the
benefits of exercise and an individualized exercise instruction session based on the results
of their baseline testing and their individual preferences. Each program will include
ability specific stretching/flexibility, progressive resistive strengthening, and aerobic
exercise. Necessary equipment for the strengthening (weights, stretch cords, elastic bands)
and aerobic components will also be provided. A videotape demonstrating each exercise in the
intervention will be given to the participant and their parent."
Detailed written instructions, along with a book to log exercise, will also be provided.
Stickers and small toys will be provided for the parents to give to their children for
completing their exercises. Participants will receive a weekly phone call from an exercise
coach, to answer questions and to progress the intervention. Participants will also receive
counseling and review/progression of the exercise intervention at each usual clinic visit
(approximately monthly). During the pilot study, participants will continue to receive the
intervention for six months, with weekly phone calls tapering to every other week after
three months. The exercise coach will be available to the participant/parent as needed via
phone and/or email throughout the intervention period.
;
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT05772000 -
Clinical Significance of Occult Central Nervous System Localization
|
||
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Active, not recruiting |
NCT03114865 -
A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06308588 -
Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
|
Phase 2 | |
Recruiting |
NCT05579132 -
A Phase Ib/II Study of CN201 in Precursor B-cell Acute Lymphoblastic Leukemia
|
Phase 1/Phase 2 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Terminated |
NCT02231853 -
Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections
|
Phase 1 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 | |
Recruiting |
NCT06195891 -
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Withdrawn |
NCT02815059 -
Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone
|
Phase 1 | |
Completed |
NCT00390793 -
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A | |
Completed |
NCT00026780 -
Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
|
||
Completed |
NCT04666025 -
SARS-CoV-2 Donor-Recipient Immunity Transfer
|
||
Not yet recruiting |
NCT06350994 -
Early Assessment of Cardiac Function After Treatment With CAR-T Cells
|
||
Withdrawn |
NCT04282174 -
CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies
|
Phase 2 | |
Not yet recruiting |
NCT04488237 -
Vitamin D and Methotrexate Adverse Effects
|
||
Completed |
NCT02544438 -
Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
|
Phase 1/Phase 2 |